JAZZ
Jazz Pharmaceuticals
November 3, 2026 · pre-market
- Rarity
- 2.09
- Peak move
- +8.84%
- Float cap
- $12.5B
Still running — rarity and peak move can only rise from here.
Jazz Pharmaceuticals is a global biopharmaceutical company that develops and markets medicines for serious diseases with limited or no therapeutic options. It sells branded therapies to patients and prescribers through two main franchises: neuroscience, chiefly the low-sodium oxybate Xywav for narcolepsy and idiopathic hypersomnia and the cannabidiol drug Epidiolex for severe epilepsies, and oncology, including Zepzelca, Rylaze, Ziihera, Vyxeos and Modeyso.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.